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ABSTRACT 
Measurement of fecal cytokines has been used as a marker of intestinal inflammation in people and correlates with en- 
doscopic findings. The aim of this study was to evaluate the use of canine-specific enzyme-linked immunosorbant as- 
says (ELISAs) for quantification of cytokines in canine fecal samples as a non-invasive biomarker. Interleukin (IL)-6, 
-8, -10, -23/12p40 and TNF- were assessed by using spiked fecal samples from 3 healthy dogs. Standard curve valida- 
tion was performed, and the impact of time to freeze, duration of storage and number of freeze-thaw cycles on cyto- 
kine concentration were also examined. All the cytokines assayed could be detected, with varying accuracy. The mean 
coefficient of variation (CV) for all standard curves ranged from 2.95% - 9.8%. The mean intra-assay CV ranged from 
3.1% - 11.14%, and inter-assay CV from 4.36% - 18.83%. Recovery of IL-23 was poor (7.23% - 17.12%), precluding 
further interpretation of stability studies. Mean recovery did not appear to be affected by time to freeze and repeat 
freeze-thaw cycles in all cytokines investigated. Recovery for all cytokines after short-term storage of 30 days at −80˚C 
showed a recovery of <70% or >130%. In conclusion, although fecal IL-6, -8, -10, and TNF- could be used as bio- 
markers of intestinal inflammation in the dog, the quality of laboratory performance and poor recovery at lower concen- 
trations limit their application. Bench-top and freeze-thaw stability was acceptable, and samples should ideally be ana- 
lyzed within a week. Investigation involving dogs with acute and chronic inflammatory intestinal disease is required to 
determine the role of this methodology in a clinical setting. 
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1. Introduction 
Existing diagnostic procedures to identify intestinal in- 
flammation in dogs are generally expensive or invasive. 
Histopathology is currently considered the gold standard 
for diagnosis of active intestinal inflammation, with bi- 
opsies obtained endoscopically or surgically. Biopsies, 
however, are subject to intra- and inter-observer variation 
and may be of variable sample quality [1-3]. Additionally, 
in clinical gastroenterology the aim of treatment is to 
induce remission, which is defined by the American 
Food and Drug Administration as “an absence of in- 
flammatory symptoms in conjunction with evidence of 
mucosal healing” [4]. Repeated endoscopy and biopsies 
are not always permitted in veterinary practice, and cur- 
rent laboratory tests are unable to establish clearly when 
remission is reached. The uses of disease activity indices 
aid in monitoring the progress of patients, but themselves 
have subjectivity in their scoring, or may be influenced  
by the presence of co-morbidities [5-7]. 
Fecal biomarkers are a heterogeneous group of sub- 
stances that leak from, or are generated by, inflamed in- 
testinal mucosa [7]. An ideal fecal biomarker should be 
non-invasive, reproducible, sensitive, specific, and with 
clear reference intervals able to distinguish between 
normal and diseased dogs. A variety of potential markers 
have been assessed in dogs to date, including calprotectin, 
Alpha1-proteinase inhibitor and S100A12 [8]. With peo- 
ple, fecal excretion of 111Indium-labeled leukocytes cur- 
rently serves as the gold standard fecal marker of in- 
flammation [7,8]. However, its use, along with other 
techniques such as fecal excretion of 51Chromium-la- 
beled red cells or radio-labeled proteins has not been 
widely adopted in the medical or veterinary field due to 
issues of radiation exposure and the need for fecal col- 
lection over 4 days [7,8]. Other fecal markers measure 
gastrointestinal protein loss, such as alpha1-proteinase 
inhibitor in dogs, which is protected from intestinal pro- 
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teases [9,10]. However, these markers are not specific for 
inflammatory disease [7,11,12]. Furthermore, these fecal 
tests are not widely available [13]. 
Cytokines are effector proteins that regulate immunity, 
and are potential biomarkers for diagnostic and therapeu- 
tic monitoring being more reflective of general inflame- 
mation. Fecal cytokines such as Tumor Necrosis Fac- 
tor-Alpha (TNF-) have been shown to be a useful 
marker of disease activity in people with inflammatory 
bowel disease (IBD) and to correlate well with endo- 
scopic findings [14,15]. Fecal measurement of anti-in- 
flammatory cytokines interleukin (IL)-4 and -10 has been 
shown to increase with clinical resolution of IBD [16], 
whilst both IL-2 and interferon (IFN)- have been shown 
to significantly increase in people with Norovirus associ-
ated diarrhea [17]. As well, IL-8 and IL-1 were in-
creased in some patients with enteroaggregative Es- 
cherichia coli infection [18]. 
It is thought that different factors e.g. bacterial patho- 
gen-associated molecular patterns or activation of toll- 
like receptors may incite different combinations of cyto- 
kines which are predominantly T helper (Th)-1 (e.g. IL-1, 
-8, TNF-) or Th-2 (IL-6, IL-10) mediated [19]. Recent 
studies in men have shown that a distinct subset of T 
helper cells (Th17) drives inflammation and pathology in 
the human gut. The mechanism by which this occurs is 
unknown but it is thought to involve a milieu of cyto-
kines including IL-17 and -23 [20,21]. The aim of this 
study was to investigate the use of enzyme linked immu- 
nosorbant assay (ELISA) for detection of IL-6, -8, -10, 
-23/12p40 and TNF-α in canine fecal samples. As this 
bioanalytical method has been validated for use with 
other matrixes in the same species, only a partial valida- 
tion was performed [22]. 
2. Material and Methods 
2.1. Samples 
Assay validation was performed on fecal samples col- 
lected immediately after voiding from three healthy staff- 
owned dogs and consisted of the following breeds: Japa- 
nese spitz (female, neutered), Border collie (male, neu- 
tered), and a golden retriever (male, neutered). All three 
dogs were between 2 - 3 years of age and had no history 
of gastrointestinal signs or weight loss in the 2 months 
prior to sample collection. All samples were collected in 
the morning. No medications including NSAIDS, antibi- 
otics or corticosteroids had been administered for at least 
3 months prior to sample collection, apart from worming 
prophylaxis. 
2.2. Collection and Processing of Fecal Samples 
Fecal samples were collected and were kept at 2˚C - 4˚C 
until processed, within an hour of submission. Samples  
were divided into 1 g aliquots and placed in polypropyl- 
ene tubes with 5 mL of protease inhibitor cocktail P83401 
diluted 1:100. The mixture was vortexed for one minute 
or until the sample was thoroughly homogenized. Sam- 
ples were then centrifuged at 1200 - 1500 RCF for 5 
minutes at 4˚C, and 0.5 mL aliquots of the supernatant 
were separated into polypropylene tubes, stored on dry 
ice, then at −80˚C until assayed. Samples were kept on 
ice at all other times during processing. Undiluted su- 
pernatant samples were spiked with moderately low lev- 
els of each cytokine as the validation sample (VS) for 
validation studies. All three VSs were included with each 
validation run and were analyzed in duplicate. Assays 
were performed over several days, with no more than one 
run per day per ELISA being evaluated. All assays were 
performed by a single operator (NP). 
2.3. IL-6, -8, -10 and TNF- Assays 
Canine immunoassays for IL-6, -8, -10 and TNF-2 were 
used according to manufacturer’s instruction, with the 
exception of overnight incubation of fecal samples at 4˚C 
to increase sensitivity at the lower limit of detection 
(LLOD). All samples were run in duplicate. 
2.4. IL-12/23p40 Assay 
An IL-23 immunoassay was developed from a canine 
IL-12/23p40 assay development kit3. The assay employs 
the quantitative sandwich enzyme immunoassay technique 
and is performed on 96-well flat-bottom, high-binding 
plate4. The plate was coated with 100 L/well goat anti- 
canine IL-12/23p40 as the capture anti-canine mono- 
clonal antibody and incubated overnight at 4˚C. Subse- 
quent steps were carried out at room temperature. 
The blocking agent and reagent diluent were 1 % BSA 
in phosphate buffered saline, wash buffer was 0.05% 
Tween 20 in phosphate buffered saline, and the substrate 
solution a 1:1 mixture of hydrogen peroxide and tetrame- 
thylbenzidine. Serial two-fold dilutions were performed 
on a 4000 pg/mL recombinant canine IL-12/23p40 stan- 
dard to generate an eight-point curve. A biotinylated goat 
anti-canine IL-12/23p40 and streptavidin is used to pre- 
cipitate a color change that is proportional to the amount 
of IL-12 and IL-23p40 bound in the initial step. The re- 
action is stopped by 2N sulphuric acid and the optical 
density of each well is read immediately at 450 nm, and 
540 nm. 
2.5. Standard Curve Validation 
All standard curves were prepared using the supplied 
1Sigma Aldrich, Missouri, USA.  
2QuantikineTM Canine Immunoassay kits (catalogue numbers CA6000
CA8000, CA1000, CATA00) R&D Systems, Minneapolis, USA. 
3Canine IL23/12p40 Duoset (catalogue number DY1969) R&D Sys-
tems, Minneapolis, USA. 
4Greiner Bio-one, Frickenhausen, Germany. 
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cytokine standards that were reconstituted with the re- 
agent diluents to produce a two-fold dilution series on the 
day of the assay. This produced at least six non-zero stan- 
dards (excluding blank and anchor points). Back calcula-
tions were obtained from six standard curves performed 
for each cytokine. ELISA validation included description 
of the standard curves with CV of the back-calculated 
values and Square of Pearson’s Correlation Coefficient 
(R2) calculated for each of the cytokines assayed. Ac-
ceptance criteria required that the CVs for at least 75% of 
the calibration standards should be <20% [23]. 
The upper limit of detection (ULOD) was measured 
using the highest standard concentration value measured 
for that cytokine. Sample analytes of biological systems 
are predicted not to exceed ULOD based on previous 
studies on fecal cytokines [13,17,24]. 
2.7. Intra-Assay and Inter-Assay Precision 
2.6. Limits of Detection 
The LLOD was calculated using the mean and standard 
deviation of the absorbance of the blank samples (assay 
diluent) to define the lowest concentrations of fecal cyto- 
kines that can be reliably distinguished. The LLOD was 
determined based on manufacturer’s guidelines by add- 
ing two standard deviations to the mean optical density 
of the zero standard replicates and calculating the corre- 




2 S.D. absorbance zero standard 0 pg mL /
absorbance 0 pg mL lowest standard pg mL





All three VSs were used to calculate the intra-assay and 
inter-assay precision. The nominal spiked concentrations 
can be found in Table 1. Four pairs of each sample were 
run within the same assay, as well as in duplicates on 
three separate days. Inter- and intra-assay CV was used 
as criteria to validate the precision of ligand-binding as- 
says with a CV of <25% deemed acceptable [23]. Dilu- 
tion series on the day of the assay. This produced at least 
six non-zero standards (excluding blank and anchor 
points). Back calculations were obtained from six stan- 
dard curves performed for each cytokine. ELISA valida- 
tion included description of the standard curves with CV 
of the back-calculated values and Square of Pearson’s 
Correlation Coefficient (R2) calculated for each of the 
cytokines assayed. Acceptance criteria required that the 
CVs for at least 75% of the calibration standards should 
lie within 20% [23]. 
 
Table 1. Overview of results for initial validation of IL-6, -8, -10, -23 and TNF- ELISA in 3 dogs. 
 IL-6 IL-8 IL-10 IL-23 TNF- 
Standard Curve Validation     
CV* of standards % 
(mean ± std dev) 9.80 ± 4.65 2.95 ± 3.61 8.08 ± 3.74 7.84 ± 5.63 3.25 ± 2.06 
Mean R2 value 0.998 0.999 0.996 0.960 0.991 
Example of best 
fit trendline y = 0.0010x ± 0.1102 y = 0.0030x − 0.0069 y = 0.0028x ± 0.0867 y = 0.0025x ± 0.1564 y = 0.0047x ± 0.1354
Sensitivity      
LLOD† (pg/mL) 4.90 0.99 0.95 1.11 1.19 
ULOD‡ (pg/mL) 2000.00 1000.00 1000.00 4000.00 500.00 
Validation Samples      
Nominal concentration 
of VS§ pg/mL 48.8 31.0 31.0 61.0 45.5 
Assayed conc of VS pg/mL 
(mean ± std dev) 81.7 ± 22.89 24.69 ± 3.01 11.91± 2.16 10.84 ± 18.79 23.5 ± 15.48 
Intra-assay CV (%) 3.10 4.96 3.10 11.14 4.25 
Inter-assay CV (%) 11.52 18.83 4.36 6.25 4.08 
Accuracy Studies (mean recovery ± std dev) %    
Low spike (%) 109.97 ± 9,88 66.38 ± 3.44 83.44 ± 9.63 17.12 ± 19.00 65.76 ± 7.73 
Med spike (%) 91.17 ± 2.3 75.11 ± 2.92 97.54 ± 10.33 7.23 ± 7.42 83.46 ± 5.18 
High spike (%) 100.31 ± 1.84 86.84 ± 2.14 104.70 ± 5.52 14.52 ± 12.76 90.91 ± 2.94 
Stability Studies (mean recovery ± std dev) %    
3 hours on bench 82.03 ± 3.56 95.95 ± 1.88 78.92 ± 7.95 NA 81.22 ± 10.36 
3 freeze-thaw cycles 94.38 ± 9.06 93.27 ± 1.36 73.80 ± 8.07 NA 78.15 ± 12.71 
1 month at −80˚C 130.84 ± 12.79 133.17 ± 9.84 52.00 ± 17.81 NA 28.29 ± 6.40 
*Coefficient of variation; †Lower limit of detection; ‡Upper limit of detection; §Validation Sample. 
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2.8. Recovery 
Undiluted supernatant samples from all three dogs were 
used as baselines for the spike and recovery experiments. 
These samples were spiked with low, moderate and high 
concentrations of the respective recombinant cytokines. 
The spiking levels were determined from the assay de- 
tection limits, with the low spike being two-fold above 
the LLOD and the high spike two-fold below the ULOD. 
Recovery was quantified as a comparison of an observed 
(assayed) result to its theoretical true value, expressed as 
a percentage of the nominal (theoretical) concentration 




Recovery % : measured concentration /
neat concentration  nominal concentration 100  (2) 
2.9. Stability Studies 
Short-term storage at room-temperature and −80˚C, as 
well as freeze-thaw stability was assessed [23,25,26]. 
Bench-top stability was assessed at room temperature for 
up to 3 hours, as well as short-term storage stability at 
−80˚C for 1 month. The acceptance criterion was defined 
as a mean recovery of between 70% - 130% [23], com- 
pared to their respective reference baseline samples as- 
sayed i.e. recovery = (assayed concentration of vari- 
able/assayed concentration of baseline sample) × 100. 
Freeze-thaw stability was assessed for up to three cycles. 
Freeze/thaw intolerance was defined as a recovery of 
<70% compared to original concentrations. 
3. Results 
An overview of the ELISA validation results for IL-6, -8, 
-10, -23 and TNF- is shown in Table 1. All cytokines 
could be detected, with varying accuracy. The mean CV 
of the standard curves of IL-6, -8, -10, -23, and TNF- 
ranged from a minimum of 2.95% to 9.80%. The R2 ob- 
tained for standard curves derived from each assay 
ranged from 0.960 to 0.999 (mean of 0.988). The mean 
intra-assay CV ranged from 3.10% to 11.14%, and in- 
ter-assay CV from 4.36% to 18.83%. The recovery of the 
low spike for IL-8 and TNF- were 66.38% and 65.76% 
respectively. There was also poor recovery of IL-23 from 
fecal samples spiked with IL-23, with a recovery of 
7.23% - 17.12%. This precluded any further interpreta- 
tion of the test results from the bench-top, storage and 
stability studies for that particular cytokine. The recovery 
for all other concentrations for the spike-and-recovery 
study was more than 75%. 
Results for all bench-top and freeze thaw stability 
studies fell within acceptance criteria of recovery be- 
tween 70% - 130%. The mean recovery ranged from 
78.92% - 95.95% for samples left for 3 hours on bench- 
top at room temperature. The mean recovery ranged from 
73.80% - 94.38% for samples that were subjected to 
three freeze-thaw cycles. Finally, the samples were found 
to be intolerant to storage at −80˚C for one month, with 
all cytokines assayed having a mean recovery of <70% or 
>130% (range of 28.29-133.17%). 
4. Discussion 
There have been several studies using semi-quantitative 
methods and real-time reverse transcriptase polymerase 
chain reaction in intestinal biopsy samples to investigate 
the role of cytokines in mediation of chronic intestinal 
inflammation in dogs [27-29]. Initial studies showed in- 
creased expression of transcripts encoding IL-2, -5, 
-12p40 TNF- and Transforming Growth Factor- in 
dogs with inflammatory bowel disease [30,31], but more 
recent investigations into intestinal cytokine expression 
have shown no difference between diseased and control 
samples [27,32]. The choice of cytokines assayed in this 
study was based on previous fecal cytokine studies in 
people with acute or chronic enteropathies, assessing 
both Th1 and Th2 subsets [14,16,18]. In addition, IL-23, 
produced by the distinct subset of T helper cells (Th17), 
was also included, due to its role in driving inflammation 
and pathology in the gut [33-35]. 
Studies have shown undetectable or low concentra- 
tions of cytokines in plasma and serum samples from 
healthy subjects [36,37]. Cytokine IL-2, -4, -5, -10, 
TNF-, IFN- and IFN- concentrations documented in 
pathogen induced diarrhea ranged from 0.0 - 51.4 pg/mL 
[17]. As preliminary results showed undetectable con- 
centrations in native samples of the cytokines assayed, 
and fecal cytokine concentrations in diseased dogs have 
not been documented to date, it was decided that our VSs 
should be spiked with moderate concentrations of the 
respective cytokines to mimic concentrations found in 
human diseased states. The assays were then evaluated 
based on these VSs for reproducibility and accuracy. 
From the results, the reproducibility of the standard 
curves in the assays was acceptable. An increase in stan- 
dard deviation and CV at the lower concentrations was 
noted. The higher variation in the assay of lower concen- 
trations of cytokine is not unexpected [23,36]. However, 
the clinical implication of this observation is unknown as 
the presence and degree of fecal cytokine aberrations in 
dogs with acute and chronic gastrointestinal disease has 
not yet been documented. Assay accuracy may be af- 
fected if concentrations occur at the lower end of the 
standard curve. Assay precision otherwise appears to be 
adequate and meets the recommended criteria of <20% 
for intra-assay CV and <25% for inter-assay CV for 
validation of ligand-binding assays [25,38]. 
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In this study, there were significant inconsistencies in 
cytokine recovery for the low spikes of IL-8 and TNF-. 
The recovery of IL-23 for all spikes was markedly poor 
and precluded further interpretation of stability studies. 
The poor recoveries observed may be due to proteases 
that were not inactivated by the protease-inhibitor cock- 
tail at initial sample handling, or the presence of non- 
specific inhibitors. Both of these effects would be more 
apparent with lower cytokine concentrations. Unfortu- 
nately, effects of other protease inhibitors were not as- 
sessed as part of our investigations. Depending on the 
working concentrations of IL-8 and TNF- in a clinical 
setting, these observations may limit the capacity of these 
ELISAs to be used as a quantitative test. However, it 
may still prove useful as a qualitative or semi-quantita- 
tive measure of disease activity. 
Current recommendations for cytokine measurement 
are to process and freeze plasma/serum samples within 
an hour of collection [36]. In this study, recovery was 
still within acceptable limits of 70% - 130% in samples 
left for three hours at room temperature. Sample stability 
was also deemed acceptable for up to three freeze-thaw 
cycles. 
Finally, the authors investigated the stability of cyto- 
kines over short-term storage. In the clinical and experi- 
mental setting, stability over longer term storage is ideal 
to guarantee confidence in the results obtained. Most 
cytokines in serum have been shown to be stable for up 
to 2 years, although IL-6 and IL-10 degraded up to 50% 
of baseline values within 2 - 3 years at −80˚C [36]. Due 
to the unpredictable effect of proteases in fecal samples, 
it was decided to re-assay the samples at a 1 month time 
point, whereby all the cytokines assayed did not fulfill 
the acceptance criteria of having a recovery between 
70% - 130%. As all other validation assays were per- 
formed within a week of collection and processing, and 
the authors recommend that assays be performed during 
that time frame. Human studies where TNF- has been 
undetected or measured have unfortunately not specified 
their respective storage times before assay to assess 
comparison of performance [17,25]. 
There are multiple limitations to the validation study 
performed, with the small number of subjects being the 
major one. Parallelism was also not proven given the 
negligible cytokine concentrations in the neat samples 
assayed. However, the authors have decided to proceed 
with validation as higher endogenous levels of the cyto- 
kines are expected in diseased samples. Also, although a 
spiked sample of the biological matrix was used as a VS 
to mimic clinical samples; this may differ from an en- 
dogenous protein and its behavior with assay perform- 
ance. Finally, given the unknown endogenous working 
range, second VS of high concentration should also have 
been assayed as part of the validation study [23]. 
5. Conclusion 
In summary, detection of fecal cytokines (IL-6, -8, -10, 
and TNF-) by ELISA may be of use as non-invasive 
biomarker of inflammation in the dog, however IL-12/ 
23p40 could not be reliably measured. From the data in 
this study, the authors propose that clinical fecal samples 
are processed as soon as possible or within an hour of 
sample collection and are analyzed within a week. This 
study provides preliminary information for research in 
dogs with inflammatory intestinal disease. Further inves- 
tigation is needed to determine if fecal cytokines can be 
correlated with clinical signs as a predictor of disease. 
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